NCT00057447View on ClinicalTrials.gov

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

June 30, 2004

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Interferon Gamma-1b

100 or 200 mcg, SQ, 3x per week

DRUG

Rituximab

375 mg per square meters, IV, 1x per week

Trial Locations (1)

94005

Intermune Inc, Brisbane

Sponsors

Lead Sponsor

InterMune
All Listed Sponsors
lead

InterMune

INDUSTRY